Navigation Links
SemBioSys announces 2007 financial and operational results
Date:3/17/2008

h an expanded focus on insulin and Apo AI, as well as increased field planting costs for ImmunoSphere(TM).

General and administrative expenses for the twelve-month period ended December 31, 2007 were $4,528,184 compared with $4,013,653 for the corresponding period last year. The difference is due mainly to the increased general and administration support required for the overall increased company activity including newly added staff and the additional related support costs as well as increased recruiting activities for senior management in Botaneco.

Intellectual property costs for the twelve-month period ended December 31, 2007 were $1,569,095 compared with $3,467,045 for the twelve-month period ended December 31, 2006. This difference is primarily attributable to a $1,516,906 non-cash license fee incurred in the second quarter of 2006 for the acquisition of technology from Syngenta Crop Protection AG in exchange for warrants.

Business development costs for the twelve-month period ended December 31, 2007 were $1,213,634, compared with $745,964 for the corresponding period last year. The difference is primarily related to the commercialization activities of Botaneco including increased staffing levels and increased contractor and consulting time.

Net loss for the twelve-month period ended December 31, 2007 was $15,418,677 or $0.71 per share, compared to a net loss of $14,127,086 or $0.85 per share for the twelve-month period ended December 31, 2006.

As at December 31, 2007 the Company had cash and cash equivalents totaling $20,444,013 and a net positive working capital balance of $19,518,408 compared to $16,328,459 and $15,576,155, respectively, at December 31, 2006. Total long-term debt at December 31, 2007 was $1,389,047 compared with $2,084,103 at December 31, 2006.

The increase in cash and working capital resulted primarily from the completion of a $14,379,010 (net of issue costs) public offering in the first quarter of 2
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
2. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
3. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys announces 2007 third quarter results
6. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
7. SemBioSys updates Apo AI development program
8. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
9. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
10. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
11. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO ... Joseph as Chief Legal Officer.  Mr. Joseph brings ... and has worked in both public and private companies, ... (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ) "Don ... general counsel and senior executive and his knowledge and ...
(Date:6/17/2013)... 2013 zuChem Inc., a leading ... nutrition, announced today that the United States Patent ... - US 8,367,346 entitled “Methods for Production of ... for producing D-Mannitol." These two patents expand zuChem's ... food sweetener products from abundant, renewable feedstocks. ...
(Date:6/17/2013)... NY (PRWEB) June 17, 2013 With the ... the launch of the Chief Medical Officer Summit for Emerging ... will take place in San Francisco on November 4-5, ... For the first time, West Coast Chief Medical Officers at ... Dr. Elizabeth Stoner, Managing Director of MPM Capital. Valerie Bowling, ...
(Date:6/17/2013)... The ALS Therapy Development Institute (ALS TDI) will hold ... event on July 19-21, 2013. The Tri-State Trek is a three-day, ... to Greenwich, CT with the mission to ... disease). (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO ) ... passes through 46 communities and includes 12 rest stops, ...
Breaking Biology Technology:KaloBios Appoints Donald R. Joseph as Chief Legal Officer 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 4zuChem Receives Two Polyol Patents 2Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21 2ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21 3
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 2011 Asmacure Ltee, a clinical-stage biopharmaceutical ... for the treatment of asthma and other inflammatory diseases, ... chief executive officer.  With a solid foundation established at ... progresses its lead compound, a potential new treatment for ...
... KONG, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... plan to release financial results for the fourth quarter and ... 2011, after market close in the US.   ... ET on Monday, June 13, 2011 to discuss its financial ...
Cached Biology Technology:EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:6/14/2013)... World War II soldiers, "The White Cliffs of Dover" ... times. To geographers, the white cliffs mark the point ... scientists, the white cliffs are towering structures made of ... alga known as Emiliania huxleyi . "Ehux" is ... Even though the process by which the alga,s "armor" ...
(Date:6/14/2013)... OttawaJune 14, 2013Here,s a good reason to pay ... has published a paper from Ottawa researchers today, ... in the fight against cancer. The technique predicts ... cancer-killing, oncolytic viruses to overcome the natural defences ... infection. , "Oncolytic viruses are special in ...
(Date:6/13/2013)... The World Cultural Council is proud to announce that ... presentations, with its 30th Award Ceremony on Wednesday, 2nd ... and the Programme will be available shortly. , ... criteria for the Science Award of bringing "true benefit ... a scientific leader of several prestigious organizations, with significant ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Using math to kill cancer cells 22013 World Cultural Council awards 22013 World Cultural Council awards 3
... major new review of scientific knowledge on kava a ... with calming effects has left unsolved the mystery of ... in the United States, Europe, and other Western cultures sometimes ... Chemical Research in Toxicology . Line Olsen and colleagues ...
... release is available in German and Spanish ... in Chile pose a higher threat to its neighbour, Argentina, ... University of Concepcin in Chile and the Helmholtz Centre for ... In particular, 22 non-native species which occur in Chile on ...
... , This release is available in German ... protects them against diseases. The early detection of pathogens and ... work as a protective shield. However, the pathogens that cause ... suppress the natural cell wall reaction in plants. "One particularly ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3TUM researchers discover a new switch in resistance to plant diseases 2
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
NAP-2 (5C7)...
golgi reassembly stacking protein 2, 55kDa...
Biology Products: